Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.

The clinical respiratory journal

Volumn 2, Issue 2, 2008, Pages 80-85

  Hillerdal, Gunnar ^a   Sorensen, Jens Benn ^b   Sundström, Stein ^b   Vikström, Anders ^b   Hjerpe, Anders ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; LIPOSOME;

ADULT; AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECT; ERYTHEMA; FEMALE; HUMAN; MALE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PLEURA TUMOR; QUALITY OF LIFE; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; FEMALE; HUMANS; LIPOSOMES; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651007079     PISSN: None     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2008.00050.x     Document Type: Article

References (0)